[Ip-health] Re: IGWG II: Limitation on Diseases

[Hohman, David E]

Then don't complain that you don't have access.=0D
=0D
-----Original Message-----=0D
From: Judit Rius Sanjuan <judit.rius@keionline.org>=0D
To: Hohman, David E=0D
CC: Ip-health@lists.essential.org <Ip-health@lists.essential.org>=0D
Sent: Wed Nov 07 12:51:29 2007=0D
Subject: Re: [Ip-health] Re: IGWG II: Limitation on Diseases=0D
=0D
Dear Mr. Hohman,=0D
=0D
Thank you for your email. In this era of blackberries, sms, email and=0D
people going outside of the room to have a coffee, we have access to=0D
knowledge.=0D
=0D
I am sure the 49 pharmaceutical companies representatives are equally=0D
well informed, as are biotech who are actually in the room.=0D
=0D
Judit=0D
=0D
Hohman, David E wrote:=0D
> If you don't have access how do you know it's going on?=0D
>=0D
> -----Original Message-----=0D
> From: ip-health-admin@lists.essential.org <ip-health-admin@lists.essentia=
l.org>=0D
> CC: Ip-health@lists.essential.org <Ip-health@lists.essential.org>=0D
> Sent: Wed Nov 07 12:31:25 2007=0D
> Subject: [Ip-health] Re: IGWG II: Limitation on Diseases=0D
>=0D
> It seems the footnote 1 may be coming back, they are currently=0D
> discussing it in one of the drafting rooms we (NGOS) do not have access t=
o.=0D
>=0D
> Judit Rius Sanjuan wrote:=0D
>=0D
>> We have been informed that yesterday night one of the drafting group=0D
>> agreed to eliminate the footnote 1 included in the Secretariat Draft=0D
>> Global Strategy and Plan of Action.=0D
>>=0D
>> These are very good news because the footnote 1 included a=0D
>> unjustifiable limitation by listing the diseases that will be the=0D
>> focus of this global strategy and plan of action:=0D
>>=0D
>> Footnote eliminated: "The Commission=E2=80=99s definitions of Type I, Ty=
pe II=0D
>> and Type III diseases, and the specific diseases on which this draft=0D
>> strategy focuses, are as follows: Type I diseases are incident in both=
=0D
>> rich and poor countries, with large numbers of vulnerable populations=0D
>> in each. The strategy will focus on the following Type I diseases,=0D
>> increasingly prevalent in developing countries: diabetes,=0D
>> cardiovascular disease and cancer. Type II diseases are incident in=0D
>> both rich and poor countries, but with a substantial proportion of the=
=0D
>> cases in poor countries. For the purposes of the strategy, the focus=0D
>> is on HIV/AIDS and tuberculosis. Type III diseases are those that are=0D
>> overwhelmingly or exclusively incident in developing countries. For=0D
>> the purposes of the strategy, the focus is on the nine neglected=0D
>> infectious diseases that disproportionately affect poor and=0D
>> marginalized populations prioritized by the UNICEF/UNDP/World Bank/WHO=
=0D
>> Special Programme for Research and Training in Tropical Diseases:=0D
>> Chagas disease, dengue and dengue haemorrhagic fever, leishmaniasis,=0D
>> leprosy, lymphatic filariasis, malaria, onchocerciasis,=0D
>> schistosomiasis and human African trypanosomiasis."=0D
>>=0D
>>=0D
>=0D
>=0D
> --=0D
> Judit Rius Sanjuan=0D
> Attorney=0D
> judit.rius@keionline.org=0D
>=0D
> Knowledge Ecology International (KEI)=0D
> www.keionline.org / www.cptech.org=0D
> 1621 Connecticut Ave, NW, Suite 500 Washington, DC 20009 USA=0D
> Tel.: +1.202.332.2670, Ext 18  Fax: +1.202.332.2673=0D
>=0D
> _______________________________________________=0D
> Ip-health mailing list=0D
> Ip-health@lists.essential.org=0D
> http://lists.essential.org/mailman/listinfo/ip-health=0D
>=0D
=0D
=0D
--=0D
Judit Rius Sanjuan=0D
Attorney=0D
judit.rius@keionline.org=0D
=0D
Knowledge Ecology International (KEI)=0D
www.keionline.org / www.cptech.org=0D
1621 Connecticut Ave, NW, Suite 500 Washington, DC 20009 USA=0D
Tel.: +1.202.332.2670, Ext 18  Fax: +1.202.332.2673=0D
=0D